1. Home
  2. SUPN vs AI Comparison

SUPN vs AI Comparison

Compare SUPN & AI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SUPN
  • AI
  • Stock Information
  • Founded
  • SUPN 2005
  • AI 2009
  • Country
  • SUPN United States
  • AI United States
  • Employees
  • SUPN N/A
  • AI N/A
  • Industry
  • SUPN Biotechnology: Pharmaceutical Preparations
  • AI Computer Software: Prepackaged Software
  • Sector
  • SUPN Health Care
  • AI Technology
  • Exchange
  • SUPN Nasdaq
  • AI Nasdaq
  • Market Cap
  • SUPN 2.6B
  • AI 2.4B
  • IPO Year
  • SUPN 2012
  • AI 2020
  • Fundamental
  • Price
  • SUPN $54.61
  • AI $17.99
  • Analyst Decision
  • SUPN Strong Buy
  • AI Hold
  • Analyst Count
  • SUPN 3
  • AI 15
  • Target Price
  • SUPN $62.67
  • AI $24.62
  • AVG Volume (30 Days)
  • SUPN 725.2K
  • AI 7.6M
  • Earning Date
  • SUPN 11-04-2025
  • AI 12-08-2025
  • Dividend Yield
  • SUPN N/A
  • AI N/A
  • EPS Growth
  • SUPN 1411.53
  • AI N/A
  • EPS
  • SUPN 1.14
  • AI N/A
  • Revenue
  • SUPN $665,125,000.00
  • AI $372,104,000.00
  • Revenue This Year
  • SUPN $7.31
  • AI N/A
  • Revenue Next Year
  • SUPN $21.87
  • AI $11.61
  • P/E Ratio
  • SUPN $46.18
  • AI N/A
  • Revenue Growth
  • SUPN 5.55
  • AI 14.34
  • 52 Week Low
  • SUPN $29.16
  • AI $14.70
  • 52 Week High
  • SUPN $53.28
  • AI $45.08
  • Technical
  • Relative Strength Index (RSI)
  • SUPN 78.22
  • AI 47.52
  • Support Level
  • SUPN $49.95
  • AI $17.20
  • Resistance Level
  • SUPN $52.15
  • AI $18.39
  • Average True Range (ATR)
  • SUPN 1.36
  • AI 0.86
  • MACD
  • SUPN 0.30
  • AI -0.07
  • Stochastic Oscillator
  • SUPN 97.61
  • AI 30.63

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

About AI C3.ai Inc.

C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Platform, which is an end-to-end application development and runtime environment for designing, developing, and deploying AI applications: C3 AI Applications, which is a portfolio of pre-built, extensible, industry-specific, and application-specific Enterprise AI applications: and C3 Generative AI, which combines the utility of large language models. Geographically the company derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and the Rest of the World.

Share on Social Networks: